LBP-519 - A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study

Saved in:
Bibliographic Details
Published inJournal of hepatology Vol. 66; no. 1; pp. S101 - S102
Main Authors Koh, C., Surana, P., Han, T., Fryzek, N., Kapuria, D., Etzion, O., Takyar, V., Rotman, Y., Canales, R., Dahari, H., Yurdaydin, C., Glenn, J., Heller, T.
Format Journal Article
LanguageEnglish
Published Elsevier B.V 2017
Online AccessGet full text

Cover

More Information
ISSN:0168-8278
1600-0641
DOI:10.1016/S0168-8278(17)30464-6